SCNI logo

SCINAI IMMUNOTHERAPEUTICS LT

SCNINASDAQ
🏆 #5431 by market capUS Equity
$340.15▼ $22.45 (−6.60%)
Simulated price
🔔
Track SCNI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$883,534
Small Cap
📈Revenue Growth (YoY)
+97.0%
High Growth
📊Gross Margin
-222.2%
Thin
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
72
Fair
No chart data available for SCNI.

Trading Snapshot

Day Range
$336.67 – $344.03
52-Week Range
$1.43 – $16.30
Volume
$1.73B
Avg Volume
$2.26B
Shares Outstanding
20.68B
Next Earnings
Nov 29, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$467,898
P/E Ratio
—
P/S Ratio
0.4x
EPS (TTM)
$-0.01
Dividend Yield
—
Dilution (1yr)
−99.0%

Why Investors Own SCNI

  • ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SCNI logo

SCINAI IMMUNOTHERAPEUTICS LT

SCNI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +99.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-202.3%▲ +129.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −12.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −4.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
769▼ −99.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$606K▼ −$484K YoY
StockOtter · stockotter.space

About SCINAI IMMUNOTHERAPEUTICS LT

Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$435.15
▲ +27.9% Upside
High Target$476.08
Low Target$337.85
Based on 14 analysts

Latest News & Updates

🚀
Reuters·2h ago

SCINAI IMMUNOTHERAPEUTICS LT tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift SCNI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

SCINAI IMMUNOTHERAPEUTICS LT announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.